The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Man lost 54 Kgs in 6 months with MGB procedure
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
New deal strengthens Congenica’s presence in India
Subscribe To Our Newsletter & Stay Updated
